What development phase is Triethoxycaprylsilan in?

Triethoxycaprylsilan is FDA-approved (marketed).

What is the generic name of Triethoxycaprylsilan?

octyltriethoxysilane is the generic (nonproprietary) name of Triethoxycaprylsilan.

Last reviewed 2026-04-20 · How we verify

Triethoxycaprylsilan (octyltriethoxysilane)

FDA-approved active Quality 0/100

Octyltriethoxysilane (Triethoxycaprylsilan) is a marketed small molecule with a specific biological mechanism, though its primary indication and revenue figures are not specified. The key strength of this drug lies in its unique mechanism of action, which may offer a distinct therapeutic benefit. However, the primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	octyltriethoxysilane
Drug class	octyltriethoxysilane
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Triethoxycaprylsilan CI brief — competitive landscape report
Triethoxycaprylsilan updates RSS · CI watch RSS
portfolio CI